Geron Discontinues GRN1005 and Restructures to Focus on Imetelstat Development in Hematologic Malignancies and Solid Tumors with Short Telomeres
[at noodls] – Company to Host Conference Call at 8:30 a.m. ET on Tuesday, December 4 MENLO PARK, Calif., December 3, 2012 – Geron Corporation (Nasdaq: GERN) today announced that the company has discontinued development … moreView todays social media effects on GERNView the latest stocks trending across Twitter. Click to view dashboardSee who Geron is hiring next, click here […]